Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Cancer Treatment and Research Communications (2021) Vol. 27, pp. 100337-100337
Open Access | Times Cited: 77

Showing 1-25 of 77 citing articles:

Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?
Alessandro Rizzo, Antonio Cusmai, Gennaro Gadaleta‐Caldarola, et al.
Expert Review of Gastroenterology & Hepatology (2022) Vol. 16, Iss. 4, pp. 333-339
Closed Access | Times Cited: 79
Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial
Akihiro Ohba, Chigusa Morizane, Makoto Ueno, et al.
Future Oncology (2022) Vol. 18, Iss. 19, pp. 2351-2360
Open Access | Times Cited: 52
Oxadiazole: A highly versatile scaffold in drug discovery
Nisheeth C. Desai, Jahnvi D. Monapara, Aratiba M. Jethawa, et al.
Archiv der Pharmazie (2022) Vol. 355, Iss. 9
Closed Access | Times Cited: 39
Ampullary Carcinoma: An Overview of a Rare Entity and Discussion of Current and Future Therapeutic Challenges
Alessandro Rizzo, Vincenzo Dadduzio, Lucia Lombardi, et al.
Current Oncology (2021) Vol. 28, Iss. 5, pp. 3393-3402
Open Access | Times Cited: 49
Tubulocystic Carcinoma of Bile Ducts
Francesca Masetto, Andrea Mafficini, Burcu Saka, et al.
The American Journal of Surgical Pathology (2024) Vol. 48, Iss. 9, pp. 1082-1092
Closed Access | Times Cited: 5
Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways
Rattanaporn Jaidee, Veerapol Kukongviriyapan, Laddawan Senggunprai, et al.
Life Sciences (2022) Vol. 296, pp. 120427-120427
Closed Access | Times Cited: 19
The Role of HER2 Status in the Biliary Tract Cancers
Rüveyda Ayasun, Muhammet Özer, İlyas Şahin
Cancers (2023) Vol. 15, Iss. 9, pp. 2628-2628
Open Access | Times Cited: 12
Systemic therapy with pemigatinib and sintilimab followed by resection for recurrent FGFR-2-positive intrahepatic cholangiocarcinoma: a case report
Yuchen Yang, Jingfeng Li, Di Ma, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Cancer Treatment and Research Communications (2021) Vol. 27, pp. 100356-100356
Open Access | Times Cited: 25
Adjuvant therapy of biliary tract cancers
Joanna Kefas, John Bridgewater, Arndt Vogel, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 10
Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management
Sakti Chakrabarti, Heidi D. Finnes, Amit Mahipal
Expert Opinion on Drug Metabolism & Toxicology (2022) Vol. 18, Iss. 1, pp. 85-98
Closed Access | Times Cited: 16
Rare Subtype of Endometrial Cancer: Undifferentiated/Dedifferentiated Endometrial Carcinoma, from Genetic Aspects to Clinical Practice
Hsiu‐Jung Tung, Ren‐Chin Wu, Chiao‐Yun Lin, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3794-3794
Open Access | Times Cited: 16
Cold plasma endoscopy applied to biliary ducts: feasibility risk assessment on human-like and porcine models for the treatment of cholangiocarcinoma
Henri Decauchy, Allan Pavy, Marine Camus, et al.
Journal of Physics D Applied Physics (2022) Vol. 55, Iss. 45, pp. 455401-455401
Open Access | Times Cited: 13
Effect of lymph node resection on prognosis of resectable intrahepatic cholangiocarcinoma: A systematic review and meta-analysis
Feiyu Li, Jiang Yong, Liyong Jiang, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 13
Precision Medicine in Cholangiocarcinoma: Past, Present, and Future
Chi-Yuan Cheng, Chiao‐Ping Chen, Chiao‐En Wu
Life (2022) Vol. 12, Iss. 6, pp. 829-829
Open Access | Times Cited: 12
Prognostic role of the systemic immune-inflammation index in biliary tract cancers: a meta-analysis of 3,515 patients
Buwen Zhang, Weiyun Yao
World Journal of Surgical Oncology (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 12
Clinical utility of a comprehensive genomic profiling test for patient with advanced biliary tract cancer
Hiroki Inada, Hideaki Miyamoto, Satoru Shinriki, et al.
International Journal of Clinical Oncology (2024)
Closed Access | Times Cited: 2
Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib
James Yu, Amit Mahipal, Richard D. Kim
OncoTargets and Therapy (2021) Vol. Volume 14, pp. 5145-5160
Open Access | Times Cited: 15
Roles of fusion genes in digestive system cancers: Dawn for cancer precision therapy
Yaqing Zhang, Jie Sun, Yongxi Song, et al.
Critical Reviews in Oncology/Hematology (2022) Vol. 171, pp. 103622-103622
Open Access | Times Cited: 11
An Insight into Cholangiocarcinoma and Recent Advances in its Treatment
Rakesh Sahu, Praveen Sharma, Ajay Kumar
Journal of Gastrointestinal Cancer (2022) Vol. 54, Iss. 1, pp. 213-226
Closed Access | Times Cited: 10
Molecular Mechanisms Linking Risk Factors to Cholangiocarcinoma Development
Ludovica Ceci, Tianhao Zhou, Ilaria Lenci, et al.
Cancers (2022) Vol. 14, Iss. 6, pp. 1442-1442
Open Access | Times Cited: 10
IDH Inhibitors and Immunotherapy for Biliary Tract Cancer: A Marriage of Convenience?
Giovanni Brandi, Alessandro Rizzo
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 18, pp. 10869-10869
Open Access | Times Cited: 10
Cholangiocarcinoma: Molecular Abnormalities and Cells of Origin
Ugo Testa, Elvira Pelosi, Germana Castelli
Technology in Cancer Research & Treatment (2023) Vol. 22
Open Access | Times Cited: 6
Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors
Alessandro Rizzo
Medicina (2021) Vol. 57, Iss. 5, pp. 458-458
Open Access | Times Cited: 13
Evaluation of drug-drug interactions of pemigatinib in healthy participants
Tao Ji, Kevin Rockich, Noam Epstein, et al.
European Journal of Clinical Pharmacology (2021) Vol. 77, Iss. 12, pp. 1887-1897
Closed Access | Times Cited: 13
Page 1 - Next Page

Scroll to top